The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Sensible approaches for reducing clinical trial costs
Abstract
Background Over the past decade, annual funding for biomedical research has more than doubled while new molecular entity approvals have declined by one third. Objective To assess the value of practices commonly employed in the conduct of large-scale clinical trials, and to identify areas where costs could be reduced without compromising scientific validity. Methods In the qualitative phase of the study, an expert panel recommended potential modifications of mega-trial designs and operations in order to maximize their value (cost versus scientific benefit tradeoff). In the quantitative phase, a mega-trial economic model was used to assess the financial implications of these recommendations. Our initial chronic disease trial design included 20,000 patients randomized at 1000 sites. Each site was assigned 24 monitoring visits and a $10,000 per patient site payment. The case report form (CRF) was 60 pages long, and trial duration was assumed to be 48 months. Results The total costs of the initial trial design were $421 million ($US 2007). Following the expert panel's recommendations, we varied study duration, CRF length, number of sites, electronic data capture (EDC), and site management components to determine their individual and combined effects upon total trial costs. The use of EDC and modified site management practices were associated with significant reductions in total trial costs. When reductions in all five trial components were combined in a streamlined pharmaceutical industry design, a 59% reduction in total trial costs resulted. When we assumed an even more streamlined trial design than has typically been considered for regulatory submissions in the past, there was a 90% reduction in total trial costs. Conclusion Our results suggest that it is possible to reduce substantially the cost of large-scale clinical trials without compromising the scientific validity of their results. If implemented, our recommendations could free billions of dollars annually for additional clinical studies. Research in the setting of clinical trials should be conducted to refine these findings. Clinical Trials 2008; 5: 75—84. http:// ctj.sagepub.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Framework for design and evaluation of complex interventions to improve health
Campbell, M. (2000) · BMJ · doi:10.1136/bmj.321.7262.694 · Cited by 3,474 · cited 1×
“, those with multiple, interconnected components) [12].”
Long-term follow-up of the West of Scotland Coronary Prevention Study
Ford, I., Murray, H., Packard, C. J., Shepherd, J., Macfarlane, P. W., & Cobbe, S. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065994 · Cited by 416 · cited 1×
“The use and value of such systems for clinical trials, especially to facilitate long-term follow-up of safety and efficacy, has recently been demonstrated in the UK [19,20].”
Background
Cited by
Ethical and Scientific Implications of the Globalization of Clinical Research
Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. A., Califf, R. M., & Schulman, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsb0803929 · Cited by 710
Self-citationWhy Most Clinical Research Is Not Useful
Ioannidis, J. P. A. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002049 · Cited by 655
Electronic health records to facilitate clinical research
Cowie, M. R., Blomster, J. I., Curtis, L. H., Duclaux, S., Ford, I., Fritz, F., Goldman, S., Janmohamed, S., Kreuzer, J., Leenay, M., et al. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1025-6 · Cited by 651
Key cost drivers of pharmaceutical clinical trials in the United States
Sertkaya, A., Wong, H.-H., Jessup, A., & Beleche, T. (2016) · Clinical Trials · doi:10.1177/1740774515625964 · Cited by 401
De testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61930-3 · Cited by 362
Metadata
- Authors
- Eisenstein, E. L., Collins, R., Cracknell, B. S., Podesta, O., Reid, E. D., Sandercock, P., Shakhov, Y., Terrin, M. L., Sellers, M. A., Califf, R. M., Granger, C. B., & Diaz, R.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2008-02
- Volume
- 5
- Issue
- 1
- Pages
- 75-84
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W2109054675
- Cited by
- 176
- References
- 3
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sensible approaches for reducing clinical trial costs. https://app.cochat.ai/papers/10.1177/1740774507087551
- The paper
- Eisenstein, E. L., Collins, R., Cracknell, B. S., Podesta, O., Reid, E. D., Sandercock, P., Shakhov, Y., Terrin, M. L., Sellers, M. A., Califf, R. M., Granger, C. B., & Diaz, R. (2008). Sensible approaches for reducing clinical trial costs. Clinical Trials. https://doi.org/10.1177/1740774507087551
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.